



09/998115

Cope

RLL-193US

**IN THE UNITED STATES PATENT & TRADEMARK OFFICE**

Applicants: ANAND *et al.*  
Patent No.: 6,914,064 B2 Examiner: BERNHARDT, Emily B.  
Grant Date: July 5, 2005 Group Art Unit: 1624  
For: 1,4-DISUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS URO-  
SELECTIVE ALPHA1-ADRENOCEPTOR BLOCKERS

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 22, 2005.

  
Kim Campbell

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Certificate  
NOV 29 2005  
of Correction

**REQUEST FOR CERTIFICATE OF CORRECTION**  
**PURSUANT TO 35 U.S.C. 254 & 35 U.S.C. 255**

Dear Sirs:

Applicants respectfully request a Certificate of Correction be issued incorporating the corrections as presented on the attached "Certificate of Correction" form.

This request is being issued pursuant to 35 U.S.C. 254 – Certificate of Correction of Patent and Trademark Office mistake & 35 U.S.C. 255 – Certificate of Correction of applicant's mistake. The basis for this request is typographical errors that have been made by both the USPTO and applicant. As indicated on the attached form, items 1, 2, 3, 4, 5, 6, 9 and 10 are typographical errors made by the USPTO and items 7 and 8 are errors that have been made by the applicant.

NOV 30 2005

Authorization is hereby given to charge any fees associated herewith to Deposit Account No. 50-0912.

Respectfully submitted,

ANAND *et al.*

By: William D. Hare  
William D. Hare, Esq.  
Reg. No., 44,739

Dated: November 22, 2005

Ranbaxy Inc.  
600 College Road East, Suite 2100  
Princeton, New Jersey 08540  
Tel: (609) 720-5608  
Fax: (609) 514-9779

NOV 30 2005

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 6,914,064 *B2*

DATED : July 5, 2005

INVENTOR(S) : Anand et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

1. References cited, Other publications - "trifiuoromethyl" should read "trifluoromethyl"
2. References cited, Other publications - "1-piperaziny|buty|" should read "1-piperaziny|butyl|"
3. Column 3, Line 8 - "against a 1A-adrenoceptors" should read "against 1A-adrenoceptors"
4. Column 3, Line 63 - "good a 1-adrenergic" should read "good 1-adrenergic"
5. Column 5, Compound No. 19 - "(Bis-4-fluorophenyf)" should read "(Bis-4-fluorophenyl)"
6. Column 5, Compound No. 28 - "(2-Methoxy-8-hydroxyphenyl)" should read "(2-Methoxy-6-hydroxyphenyl)"
7. Column 8, Line 34 - "piperazine-1-yl}" should read "piperazin-1-yl}" \*
8. Column 8, Line 38 - "piperazine-1-yl)" should read "piperazin-1-yl)" \*
9. Column 9, Compound No. 3 - "dione hydrochlolide" should read "dione hydrochloride"
10. Column 9, Compound No. 14 - "275-278 C" should read "275-276 C"

\* = our error

MAILING ADDRESS OF SENDER: **Ranbaxy Inc.**  
600 College Road East, Suite 2100  
Princeton, New Jersey 08901

PATENT NO. 6,914,064

No. of additional copies



This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**